Biology of secondary leukemia

por Brunner, Andrew M., Graubert, Timothy A.
Publicado 2018

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML

por Chen, Evan C, Fathi, Amir T, Brunner, Andrew M
Publicado 2018

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?

por Brunner, Andrew M., Fell, Geoffrey, Steensma, David P.
Publicado 2022

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?

por Brunner, Andrew M., Platzbecker, Uwe, DeZern, Amy E., Zeidan, Amer M.
Publicado 2023

Management of patients with lower-risk myelodysplastic syndromes

por Brunner, Andrew M., Leitch, Heather A., van de Loosdrecht, Arjan A., Bonadies, Nicolas
Publicado 2022

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

por Brunner, Andrew M., Gavralidis, Alexander, Ali, Najla Al, Hunter, Anthony, Komrokji, Rami, Zeidan, Amer, Sallman, David A.
Publicado 2022

Pure White Cell Aplasia and Necrotizing Myositis

por Kim, Peter Geon, Suh, Joome, Adelman, Max W., Oduro, Kwadwo, Williams, Erik, Brunner, Andrew M., Kuter, David J.
Publicado 2016

Incident adverse events following therapy for acute promyelocytic leukemia

por Kim, Peter Geon, Bridgham, Kelly, Chen, Evan C, Vidula, Mahesh K, Pozdnyakova, Olga, Brunner, Andrew M, Fathi, Amir T.
Publicado 2018

Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype

por Jalbut, Marla M., Sohani, Aliyah R., Cin, Paola Dal, Hasserjian, Robert P., Moran, Jenna A., Brunner, Andrew M., Fathi, Amir T.
Publicado 2015

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes

por Yabe, Mariko, Omarbekova, Aidana Z., Hsu, Meier, May, Hannah, Arcila, Maria E., Liu, Ying, Dogan, Ahmet, Brunner, Andrew M., Nardi, Valentina, Hasserjian, Robert P., Klimek, Virginia M.
Publicado 2021

Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations

por Leiva, Orly, Baker, Olesya, Jenkins, Andrew, Brunner, Andrew M., Al-Samkari, Hanny, Leaf, Rebecca Karp, Rosovsky, Rachel P., Fathi, Amir T., Weitzman, James, Bornikova, Larissa, Nardi, Valentina, Hobbs, Gabriela S.
Publicado 2021

Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy

por Nardi, Valentina, McAfee, Steven L, Dal Cin, Paola, Tsai, Harrison K, Amrein, Philip C, Hobbs, Gabriela S, Brunner, Andrew M, Narayan, Rupa, Foster, Julia, Fathi, Amir T, Hock, Hanno
Publicado 2022

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials

por Valtis, Yannis K., Stevenson, Kristen E., Place, Andrew E., Silverman, Lewis B., Vrooman, Lynda M., Gotti, Giacomo, Brunner, Andrew M., Nauffal, Mary, DeAngelo, Daniel J., Luskin, Marlise R.
Publicado 2021

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzu...

por Kayser, Sabine, Sartor, Chiara, Luskin, Marlise R., Webster, Jonathan, Giglio, Fabio, Panitz, Nydia, Brunner, Andrew M., Fante, Matthias, Lutz, Christoph, Wolff, Daniel, Ho, Anthony D., Levis, Mark J., Schlenk, Richard F., Papayannidis, Cristina
Publicado 2022

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials

por Shimony, Shai, Flamand, Yael, Valtis, Yannis K., Place, Andrew E., Silverman, Lewis B., Vrooman, Lynda M., Brunner, Andrew M., Sallan, Stephen E., Stone, Richard M., Wadleigh, Martha, Neuberg, Donna S., DeAngelo, Daniel J., Luskin, Marlise R.
Publicado 2023

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia

por Shimony, Shai, Liu, Yiwen, Valtis, Yannis K., Paolino, Jonathan D., Place, Andrew E., Brunner, Andrew M., Weeks, Lachelle D., Silverman, Lewis B., Vrooman, Lynda M., Neuberg, Donna S., Stone, Richard M., DeAngelo, Daniel J., Luskin, Marlise R.
Publicado 2022

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity

por Mueller, Sarah B., Dal Cin, Paola, Le, Long P., Dias-Santagata, Dora, Lennerz, Jochen K., Iafrate, A. John, Marble, Hetal Desai, Brunner, Andrew M., Weinstock, Matthew J., Luskin, Marlise R., De Angelo, Daniel J., Stone, Richard M., Nardi, Valentina
Publicado 2022

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

por Zeidan, Amer M., Borate, Uma, Pollyea, Daniel A., Brunner, Andrew M., Roncolato, Fernando, Garcia, Jacqueline S., Filshie, Robin, Odenike, Olatoyosi, Watson, Anne Marie, Krishnadasan, Ravitharan, Bajel, Ashish, Naqvi, Kiran, Zha, Jiuhong, Cheng, Wei‐Han, Zhou, Ying, Hoffman, David, Harb, Jason G., Potluri, Jalaja, Garcia‐Manero, Guillermo
Publicado 2022

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

por Sorror, Mohamed L., Storer, Barry E., Fathi, Amir T., Gerds, Aaron T., Medeiros, Bruno C., Shami, Paul, Brunner, Andrew M., Sekeres, Mikkael A., Mukherjee, Sudipto, Peña, Esteban, Elsawy, Mahmoud, Wardyn, Shylo, Whitten, Jennifer, Moore, Rachelle, Becker, Pamela S., McCune, Jeannine S., Appelbaum, Frederick R., Estey, Elihu H.
Publicado 2017

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

por How, Joan, Ren, Siyang, Lombardi‐Story, Jennifer, Bergeron, Meghan, Foster, Julia, Amrein, Phillip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno, Khachatryan, Anna, Kikuchi, Hiroto, Ng, Mei Rosa, Moran, Jenna, Narayan, Rupa, Neuberg, Donna, Ramos, Aura, Som, Tina, Vartanian, Meghan, Chen, Yi‐Bin, Duda, Dan G., Hobbs, Gabriela S.
Publicado 2022